Incyte’s success with Jakafi® (ruxolitinihb) helped persuade MorphoSys that its tafasitamab (MOR208) could also be successfully commercialized by the Wilmington, DE, biopharma, which is licensing the B cell malignancy treatment candidate through a collaboration that could generate more than $2 billion for the German cancer drug developer . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge